Clinical Trials Logo

Clinical Trial Summary

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful benefit such as improvement in pain or range of motion. However, many morbidities, such as blindness or nerve damage, cannot be fully reversed with PN shrinkage. Therefore, there remains a critical need in this patient population to determine if young participants with PN in high-risk locations may benefit from early medical intervention prior to the development of clinical problems. This study will determine whether participants with asymptomatic PN in high-risk locations can potentially benefit from early treatment with selumetinib.


Clinical Trial Description

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful benefit such as improvement in pain or range of motion. However, many morbidities, such as blindness or nerve damage, cannot be fully reversed with PN shrinkage. Therefore, there remains a critical need in this patient population to determine if young participants with PN in high-risk locations may benefit from early medical intervention prior to the development of clinical problems. This study will determine whether participants with asymptomatic PN in high-risk locations can potentially benefit from early treatment with selumetinib. Other: This trial will be operated through the Neurofibromatosis Clinical Trials Consortium, funded by the Congressionally Directed Medical Research Program under the Department of Defense which consists of 24 sites throughout the United States. Intervention: Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID. Study Duration: 7 years Partcipant Durations: 5 years ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06188741
Study type Interventional
Source University of Alabama at Birmingham
Contact Karen Cole-Plourde, BA
Phone 2055141317
Email kplourde@uab.edu
Status Not yet recruiting
Phase Phase 2
Start date August 1, 2024
Completion date August 1, 2031

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01362803 - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2
Completed NCT00352599 - Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) Phase 1
Completed NCT05005845 - NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Phase 2
Completed NCT03531814 - Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials N/A
Completed NCT00846430 - Medical Treatment of "High-Risk" Neurofibromas Phase 2
Completed NCT03433183 - SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Phase 2
Recruiting NCT05331105 - HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Phase 2
Completed NCT03310996 - Non-invasive Stimulation in Neurofibromatosis Type 1 N/A
Recruiting NCT03406208 - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing N/A
Recruiting NCT04750928 - Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas Phase 1/Phase 2
Not yet recruiting NCT06262113 - A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1 N/A
Active, not recruiting NCT04924608 - Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Phase 3
Recruiting NCT02544022 - Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
Recruiting NCT04941027 - Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
Completed NCT02153931 - Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
Completed NCT05196854 - Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1 N/A
Active, not recruiting NCT01650142 - Modifying Genes in Neurofibromatosis 1 N/A
Completed NCT05377008 - Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1 N/A
Completed NCT04879160 - Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
Recruiting NCT05735717 - MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Phase 2